Market Intelligence, Clinical Progress, and High-Purity Reagents for JAK-STAT Pathway Targeting in Oncology and Autoimmunity.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for STAT5B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (SH2 Domain) | STAT5B SH2 Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View STAT5B Products |
| Antigen (Full-Length) | STAT5B Full-Length Recombinant Protein HEK293 Expressed (Native Phosphorylation capability). High Purity (>95%). |
View STAT5B Products |
| Mutant Panel | STAT5B Constitutively Active Mutants (e.g., N642H, Y699F) Sequence Verified. For resistance mechanism studies. |
View STAT5B Products |
| Gene Delivery | STAT5B Premade Lentivirus Particles Full-length ORF for stable cell line construction. Titer >1x10^8 TU/ml. |
View STAT5B Products |
| Benchmark Ab | Anti-STAT5B (Phospho-Tyr699 Specific) Recombinant rabbit monoclonal. |
View STAT5B Products |
| Validator | STAT5B siRNA Set (3 unique sequences) For knockdown verification and assay specificity control. |
View STAT5B Products |
| Paralog Counter-screen | STAT5A SH2 Domain Protein For selectivity assays vs highly homologous STAT5A. |
View STAT5A Products |
| Upstream Kinase | JAK2 Recombinant Protein (Active) For phosphorylation cascade reconstitution assays. |
View JAK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (STAT5A vs STAT5B SH2 domain, 85% homology) | Ortholog panel: Human STAT5B SH2 + Human STAT5A SH2 proteins strictly verified by mass spec. Sequence Identity confirmed. |
| Targeting Oncogenic Mutants (N642H, Y699F) | Mutant Recombinant Proteins (N642H, Y699F) available. Sequence Verified. Theoretical MW confirmed. |
| Cell-based Nuclear Translocation | Lentivirus for stable GFP-STAT5B fusion cell lines. High titer (>1x10^8 TU/ml). |
| Lack of Phospho-specific Controls | Phospho-Tyr699 Antibody (Biosimilar sequence). Endotoxin Controlled. |
| Assay Specificity Controls (false positives, knockdown verification) | Validated siRNA included for specificity checks; Clinical Benchmark Antibodies included. |
Live STAT5B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings (general)
- ➤ Recent Patent Filings (inhibitor specific)
- ➤ Latest Inhibitor Research
Key STAT5B Mutations and Variants
The following mutations are documented in UniProt (P51692) and have functional relevance for drug discovery:
- rs2277619 (VAR_052074): dbSNP variant with potential impact on STAT5B function.
- GHISID2 variant 1 (VAR_085463): Exhibits strong growth hormone-induced phosphorylation but no subsequent transcriptional activity.
- GHISID2 variant 2 (VAR_085464): Loss of DNA-binding ability when forming homodimers with the wild-type.
These mutant proteins are available from TarMart for resistance profiling and mechanism-of-action studies.
Global Clinical Landscape & Future Outlook
The race for STAT5B therapeutics is intensifying, with major players shifting focus from broad JAK inhibitors to selective STAT5B SH2 domain blockers and proteolysis-targeting chimeras (PROTACs). As first-generation pan-JAK therapies face toxicity limitations, the next wave of R&D is targeting direct transcription factor inhibition with small molecules and PROTACs for enhanced specificity in hematologic malignancies. Hyperactive mutations like N642H (T-cell leukemias) drive demand for mutant-selective inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (SH2 Inhibitor) | Akira Therapeutics, Incyte, various biotechs | Acute Myeloid Leukemia, CML, T-cell Leukemia, Solid Tumors | STAT5A/5B Selectivity Assay (Need homolog panel proteins) |
| PROTAC / Degrader | Arvinas, Cullgen, early-stage academic/industry | Resistance Mutations, Hematological Malignancies | Ternary Complex Formation (Need purified STAT5B + VHL ligase) |
| Antisense Oligonucleotide | Ionis, Stoke Therapeutics | Solid Tumors, Autoimmune | Knockdown Efficiency Validation (Need STAT5B-specific siRNA controls) |
| Allosteric Inhibitor | Academic Consortia | Autoimmune Disorders | DNA Binding Domain Access (Need Full-length STAT5B protein) |